DDInter396 DDInter1376
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Clevidipine {u} (Compound) resembles {v} (Compound) Nitrendipine
Clevidipine {u} (Compound) binds {v} (Gene) CYP1A2
Clevidipine {u} (Compound) is included by {v} (Pharmacologic Class) Calcium Channel Antagonists
Clevidipine {u} (Compound) causes {v} (Side Effect) Acute coronary syndrome
Clevidipine (Compound) resembles Nitrendipine (Compound)
Clevidipine (Compound) binds CYP1A2 (Gene)
Clevidipine (Compound) is included by Calcium Channel Antagonists (Pharmacologic Class)
Clevidipine (Compound) causes Acute coronary syndrome (Side Effect)